High Rate of Completion with 12-Week 3HP Therapy for Latent Tuberculosis

In this observational study, the overall rate of completion was 87.2%. Adverse drug reactions occurred in more than a third of patients but led to discontinuation in only 7.5%.

An important factor in preventing active tuberculosis (TB) in the U.S. is treating those with latent infection (LTBI). For more than 50 years, the standard therapy for LTBI has been 6 to 9 months of daily self-administered isoniazid. However, newer therapies, particularly 12 directly observed (DOT) weekly doses of rifapentine plus isoniazid (3HP), appear to be as effective as standard therapy with better completion rates.

To assess the success of 3HP in routine health care settings, collaborators from the Centers for Disease Control and several state departments of health performed a postmarketing observational cohort assessment of 3HP using data from 16 TB clinics self selected by interested clinicians and program managers. Among the 3288 p…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

High Rate of Completion with 12-Week 3HP Therapy for Latent Tuberculosis

Topics

Reviewing Author